Non-steroidal anti-inflammatory drug use and cervical cancer risk: A case-control study using the Clinical Practice Research Datalink

J. C. Wilson; M. A. O'Rorke; J. A. Cooper; L. J. Murray; C. M. Hughes; G. J. Gormley; L. A. Anderson

doi:10.1016/j.canep.2013.08.010

Non-steroidal anti-inflammatory drug use and cervical cancer risk: A case-control study using the Clinical Practice Research Datalink

J. C. Wilson, M. A. O'Rorke^*, J. A. Cooper, L. J. Murray, C. M. Hughes, G. J. Gormley, L. A. Anderson

^*Corresponding author for this work

Queen's University Belfast

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have many anticarcinogenic properties via the inhibition of cyclooxygenase 2 (COX-2). Only one study, a cohort study examining risk of all cancers, investigated their role in cervical cancer with inconsistent findings between non-aspirin NSAIDs and aspirin. The aim of this study was to further investigate NSAID/aspirin use and cervical cancer risk. Methods: Using the United Kingdom Clinical Practice Research Datalink, 724 women diagnosed with cervical cancer between 1 January, 1995 and December 2010 were compared to 3479 women (without cervical cancer) matched on year of birth and general practice. Conditional logistic regression analysis adjusted for smoking, sexually transmitted infections, HRT and contraceptive use, was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for cervical cancer risk among users of any oral NSAIDs, non-aspirin NSAIDs and aspirin, as assessed from primary care prescribing data. Results: Excluding the year prior to diagnosis, there was no association in adjusted analyses between ever vs. never use of an NSAID (OR 0.92, 95% CI 0.77-1.09), non-aspirin NSAID (OR 0.95, 95% CI 0.80-1.13) or low-dose aspirin (OR 1.07, 0.80-1.44) and cervical cancer risk. In analysis of daily defined doses, there was no association with cervical cancer risk comparing the highest users to non-users of NSAIDs (OR 0.98, 95% CI 0.69-1.39) or non-aspirin NSAIDs (OR 1.00, 95% CI 0.70-1.43) or low-dose aspirin (OR 1.04, 95% CI 0.59-1.81). Conclusion: This large historical cohort study found no evidence of an association between non-aspirin NSAID or aspirin use and cervical cancer risk.

Original language	English
Pages (from-to)	897-904
Number of pages	8
Journal	Cancer Epidemiology
Volume	37
Issue number	6
Early online date	14 Sept 2013
DOIs	https://doi.org/10.1016/j.canep.2013.08.010
Publication status	Published - 1 Dec 2013

Bibliographical note

Acknowledgements

Access to the CPRD database was funded through the Medical Research Council's license agreement with the UK Medicines and Healthcare Products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the authors alone. At the time of writing, Wilson JC was supported by a Department for Employment and Learning (DEL) PhD funded scholarship and O’Rorke MA was supported through the Centre for Health Improvement, Queen's University Belfast.

Keywords

Anti-inflammatory agents
Aspirin
Non-steroidal
Uterine cervical neoplasms

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canep.2013.08.010Licence: Unspecified

Cite this

@article{22a15e592e39429db537b0b53648a7d4,

title = "Non-steroidal anti-inflammatory drug use and cervical cancer risk: A case-control study using the Clinical Practice Research Datalink",

abstract = "Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have many anticarcinogenic properties via the inhibition of cyclooxygenase 2 (COX-2). Only one study, a cohort study examining risk of all cancers, investigated their role in cervical cancer with inconsistent findings between non-aspirin NSAIDs and aspirin. The aim of this study was to further investigate NSAID/aspirin use and cervical cancer risk. Methods: Using the United Kingdom Clinical Practice Research Datalink, 724 women diagnosed with cervical cancer between 1 January, 1995 and December 2010 were compared to 3479 women (without cervical cancer) matched on year of birth and general practice. Conditional logistic regression analysis adjusted for smoking, sexually transmitted infections, HRT and contraceptive use, was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for cervical cancer risk among users of any oral NSAIDs, non-aspirin NSAIDs and aspirin, as assessed from primary care prescribing data. Results: Excluding the year prior to diagnosis, there was no association in adjusted analyses between ever vs. never use of an NSAID (OR 0.92, 95% CI 0.77-1.09), non-aspirin NSAID (OR 0.95, 95% CI 0.80-1.13) or low-dose aspirin (OR 1.07, 0.80-1.44) and cervical cancer risk. In analysis of daily defined doses, there was no association with cervical cancer risk comparing the highest users to non-users of NSAIDs (OR 0.98, 95% CI 0.69-1.39) or non-aspirin NSAIDs (OR 1.00, 95% CI 0.70-1.43) or low-dose aspirin (OR 1.04, 95% CI 0.59-1.81). Conclusion: This large historical cohort study found no evidence of an association between non-aspirin NSAID or aspirin use and cervical cancer risk.",

keywords = "Anti-inflammatory agents, Aspirin, Non-steroidal, Uterine cervical neoplasms",

author = "Wilson, {J. C.} and O'Rorke, {M. A.} and Cooper, {J. A.} and Murray, {L. J.} and Hughes, {C. M.} and Gormley, {G. J.} and Anderson, {L. A.}",

note = "Acknowledgements Access to the CPRD database was funded through the Medical Research Council's license agreement with the UK Medicines and Healthcare Products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the authors alone. At the time of writing, Wilson JC was supported by a Department for Employment and Learning (DEL) PhD funded scholarship and O{\textquoteright}Rorke MA was supported through the Centre for Health Improvement, Queen's University Belfast.",

year = "2013",

month = dec,

day = "1",

doi = "10.1016/j.canep.2013.08.010",

language = "English",

volume = "37",

pages = "897--904",

journal = "Cancer Epidemiology",

issn = "1877-7821",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Non-steroidal anti-inflammatory drug use and cervical cancer risk

T2 - A case-control study using the Clinical Practice Research Datalink

AU - Wilson, J. C.

AU - O'Rorke, M. A.

AU - Cooper, J. A.

AU - Murray, L. J.

AU - Hughes, C. M.

AU - Gormley, G. J.

AU - Anderson, L. A.

N1 - Acknowledgements Access to the CPRD database was funded through the Medical Research Council's license agreement with the UK Medicines and Healthcare Products Regulatory Agency. However, the interpretation and conclusions contained in this study are those of the authors alone. At the time of writing, Wilson JC was supported by a Department for Employment and Learning (DEL) PhD funded scholarship and O’Rorke MA was supported through the Centre for Health Improvement, Queen's University Belfast.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have many anticarcinogenic properties via the inhibition of cyclooxygenase 2 (COX-2). Only one study, a cohort study examining risk of all cancers, investigated their role in cervical cancer with inconsistent findings between non-aspirin NSAIDs and aspirin. The aim of this study was to further investigate NSAID/aspirin use and cervical cancer risk. Methods: Using the United Kingdom Clinical Practice Research Datalink, 724 women diagnosed with cervical cancer between 1 January, 1995 and December 2010 were compared to 3479 women (without cervical cancer) matched on year of birth and general practice. Conditional logistic regression analysis adjusted for smoking, sexually transmitted infections, HRT and contraceptive use, was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for cervical cancer risk among users of any oral NSAIDs, non-aspirin NSAIDs and aspirin, as assessed from primary care prescribing data. Results: Excluding the year prior to diagnosis, there was no association in adjusted analyses between ever vs. never use of an NSAID (OR 0.92, 95% CI 0.77-1.09), non-aspirin NSAID (OR 0.95, 95% CI 0.80-1.13) or low-dose aspirin (OR 1.07, 0.80-1.44) and cervical cancer risk. In analysis of daily defined doses, there was no association with cervical cancer risk comparing the highest users to non-users of NSAIDs (OR 0.98, 95% CI 0.69-1.39) or non-aspirin NSAIDs (OR 1.00, 95% CI 0.70-1.43) or low-dose aspirin (OR 1.04, 95% CI 0.59-1.81). Conclusion: This large historical cohort study found no evidence of an association between non-aspirin NSAID or aspirin use and cervical cancer risk.

AB - Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) have many anticarcinogenic properties via the inhibition of cyclooxygenase 2 (COX-2). Only one study, a cohort study examining risk of all cancers, investigated their role in cervical cancer with inconsistent findings between non-aspirin NSAIDs and aspirin. The aim of this study was to further investigate NSAID/aspirin use and cervical cancer risk. Methods: Using the United Kingdom Clinical Practice Research Datalink, 724 women diagnosed with cervical cancer between 1 January, 1995 and December 2010 were compared to 3479 women (without cervical cancer) matched on year of birth and general practice. Conditional logistic regression analysis adjusted for smoking, sexually transmitted infections, HRT and contraceptive use, was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for cervical cancer risk among users of any oral NSAIDs, non-aspirin NSAIDs and aspirin, as assessed from primary care prescribing data. Results: Excluding the year prior to diagnosis, there was no association in adjusted analyses between ever vs. never use of an NSAID (OR 0.92, 95% CI 0.77-1.09), non-aspirin NSAID (OR 0.95, 95% CI 0.80-1.13) or low-dose aspirin (OR 1.07, 0.80-1.44) and cervical cancer risk. In analysis of daily defined doses, there was no association with cervical cancer risk comparing the highest users to non-users of NSAIDs (OR 0.98, 95% CI 0.69-1.39) or non-aspirin NSAIDs (OR 1.00, 95% CI 0.70-1.43) or low-dose aspirin (OR 1.04, 95% CI 0.59-1.81). Conclusion: This large historical cohort study found no evidence of an association between non-aspirin NSAID or aspirin use and cervical cancer risk.

KW - Anti-inflammatory agents

KW - Aspirin

KW - Non-steroidal

KW - Uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84888307464&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2013.08.010

DO - 10.1016/j.canep.2013.08.010

M3 - Article

C2 - 24042024

AN - SCOPUS:84888307464

SN - 1877-7821

VL - 37

SP - 897

EP - 904

JO - Cancer Epidemiology

JF - Cancer Epidemiology

IS - 6

ER -

Non-steroidal anti-inflammatory drug use and cervical cancer risk: A case-control study using the Clinical Practice Research Datalink

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this